Why the study?
Does fenofibrate improve endothelial function, adiponectin levels, and insulin sensitivity in patients with primary hypertriglyceridemia?
Population
46 patients with primary hypertriglyceridemia (24 with metabolic syndrome)
Comparison
Fenofibrate 200 mg daily for 8 weeks vs Placebo for 8 weeks (crossover design)
Design
RCT, randomized, double blind, placebo controlled
Follow-up
8 weeks
Authors
Loading...
Fenofibrate improves endothelial function and adiponectin in hypertriglyceridemia; extends pleiotropic benefits beyond lipids in this RCT.
Does fenofibrate improve endothelial function, adiponectin levels, and insulin sensitivity in patients with primary hypertriglyceridemia?
Fenofibrate therapy improves endothelial function, reduces inflammatory markers, and enhances insulin sensitivity and adiponectin levels in patients with primary hypertriglyceridemia.
Koh et al. (2005) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: